Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Early subcutaneous administration of etanercept (Enbrel) prevents from hyperoxia-induced lung injury.

1 , ,

Experimental lung research

Informa Healthcare

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Both hyperoxia-induced proapoptotic sensitization of alveolar type II cells (TII cells) and high-stretch mechanical ventilation induced pulmonary inflammation are tumor necrosis factor alpha (TNFalpha) mediated. Therefore, binding of free TNFalpha should protect from TNFalpha-mediated acute lung injury and ameliorate the subsequently developing chronic lung disease. Here, the authors show that a single subcutaneous pretreatment of rat with etanercept, a recombinant p75 TNF receptor 2 human immunoglobulin G1 (IgG1) construct, inhibits the hyperoxia-induced and TNFalpha-mediated increase in the expression of TNFalpha receptor, the activation of caspase 3 in TII cells, and, as an early indicator of lung injury, the capillary-alveolar leakage and granulocyte number in lung lavage. The authors assume that subcutaneous administration of etanercept might be suitable to prevent acute lung injury and its sequelae induced by hyperoxic ventilation of premature neonates and critically ill patients.

      Related collections

      Author and article information

      Affiliations
      [1 ] Klinik für Neonatologie, Charité Universitätsmedizin Berlin, Berlin, Germany.
      Journal
      Exp. Lung Res.
      Experimental lung research
      Informa Healthcare
      1521-0499
      0190-2148
      Nov 2009
      : 35
      : 9
      19916860
      10.3109/01902140902887430
      10.3109/01902140902887430

      Comments

      Comment on this article